









Markets
/
Stocks
/
nasdaq-celu
/

Celularity Inc

CELU



View Detailed Chart

1.840USD

+0.120+6.98%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

45.28MMarket Cap

LossP/E TTM



Celularity Inc

1.840

+0.120+6.98%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+6.98%

5 Days

-4.66%

1 Month

-13.62%

6 Months

+16.09%

Year to Date

-11.54%

1 Year

+18.71%

View Detailed Chart

TradingKey Stock Score of Celularity Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Celularity Inc's Score

Industry at a Glance

Industry Ranking

101 / 159

Overall Ranking

257 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

6.000

Target Price

+248.84%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Celularity Inc Highlights

StrengthsRisks

Celularity Inc. is a regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Interfyl and Rebound products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 201.64% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 54.22M.

Fairly Valued

The company’s latest PE is -0.58, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.54M shares, decreasing 13.74% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 500.13K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.90.